745 related articles for article (PubMed ID: 22943930)
21. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
22. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
23. [Aspartate aminotransferase (AST) more than alanine aminotransferase (ALT) levels predict the progression of liver fibrosis in chronic HCV infection].
Stránský J; Ryzlová M; Striteský J; Horák J
Vnitr Lek; 2002 Oct; 48(10):924-8. PubMed ID: 16737138
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF
Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494
[TBL] [Abstract][Full Text] [Related]
25. Histopathological features of liver and its relation to serum transaminase levels in 91 cases of anti-HBe-positive chronic hepatitis B.
Hasanjani Roushan MR; Hajiahmadi M; Shafaie S
Int J Clin Pract; 2005 Jul; 59(7):791-4. PubMed ID: 15963206
[TBL] [Abstract][Full Text] [Related]
26. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.
Pockros PJ; Schiff ER; Shiffman ML; McHutchison JG; Gish RG; Afdhal NH; Makhviladze M; Huyghe M; Hecht D; Oltersdorf T; Shapiro DA
Hepatology; 2007 Aug; 46(2):324-9. PubMed ID: 17654603
[TBL] [Abstract][Full Text] [Related]
27. Lamivudine as initial treatment for chronic hepatitis B in the United States.
Dienstag JL; Schiff ER; Wright TL; Perrillo RP; Hann HW; Goodman Z; Crowther L; Condreay LD; Woessner M; Rubin M; Brown NA
N Engl J Med; 1999 Oct; 341(17):1256-63. PubMed ID: 10528035
[TBL] [Abstract][Full Text] [Related]
28. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies.
Zuckerman E; Zuckerman T; Douer D; Qian D; Levine AM
Cancer; 1998 Sep; 83(6):1224-30. PubMed ID: 9740089
[TBL] [Abstract][Full Text] [Related]
29. Intake of purple sweet potato beverage affects on serum hepatic biomarker levels of healthy adult men with borderline hepatitis.
Suda I; Ishikawa F; Hatakeyama M; Miyawaki M; Kudo T; Hirano K; Ito A; Yamakawa O; Horiuchi S
Eur J Clin Nutr; 2008 Jan; 62(1):60-7. PubMed ID: 17299464
[TBL] [Abstract][Full Text] [Related]
30. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
Yao G; Cui Z; Wang B; Yao J; Zeng M
Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.
de Man RA; Wolters LM; Nevens F; Chua D; Sherman M; Lai CL; Gadano A; Lee Y; Mazzotta F; Thomas N; DeHertogh D
Hepatology; 2001 Sep; 34(3):578-82. PubMed ID: 11526545
[TBL] [Abstract][Full Text] [Related]
32. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
33. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
Lai CL; Chien RN; Leung NW; Chang TT; Guan R; Tai DI; Ng KY; Wu PC; Dent JC; Barber J; Stephenson SL; Gray DF
N Engl J Med; 1998 Jul; 339(2):61-8. PubMed ID: 9654535
[TBL] [Abstract][Full Text] [Related]
34. Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial.
Bahrami H; Daryani NE; Haghpanah B; Moayyeri A; Moghadam KF; Mirmomen S; Kamangar F
Am J Gastroenterol; 2005 Apr; 100(4):856-61. PubMed ID: 15784032
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of spontaneous decline of HBV DNA in chronic hepatitis B patients in 12 weeks].
He H; Xu ZN; Cai DC; Nai N; Ling N; Zeng WQ; Shi XF; Zhao YR; Zhou Z; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):271-4. PubMed ID: 19403025
[TBL] [Abstract][Full Text] [Related]
36. [Hepatic steatosis: a common reason for elevated alanine aminotransferase levels in HBsAg-positive chronic hepatitis B patients with low HBV DNA loads].
Shi JP; Fan JG; Lou GQ; Zhang L; Hu CB; Wu R; Xun YH
Zhonghua Gan Zang Bing Za Zhi; 2008 Nov; 16(11):818-22. PubMed ID: 19032864
[TBL] [Abstract][Full Text] [Related]
37. Chronic hepatitis C in patients with persistently normal alanine transaminase levels.
Shiffman ML; Diago M; Tran A; Pockros P; Reindollar R; Prati D; Rodríguez-Torres M; Lardelli P; Blotner S; Zeuzem S
Clin Gastroenterol Hepatol; 2006 May; 4(5):645-52. PubMed ID: 16630770
[TBL] [Abstract][Full Text] [Related]
38. Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C.
Batdelger D; Dandii D; Jirathitikal V; Bourinbaiar AS
Vaccine; 2008 May; 26(22):2733-7. PubMed ID: 18455842
[TBL] [Abstract][Full Text] [Related]
39. Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients.
Shahid M; Idrees M; Nasir B; Raja AJ; Raza SM; Amin I; Rasul A; Tayyab GU
Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):788-94. PubMed ID: 24781355
[TBL] [Abstract][Full Text] [Related]
40. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H;
Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
